Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.75 |
| ▸ | CCR1 | P32246 | 6/20 | 0.55 |
| ▸ | HRH1 | P35367 | 4/20 | 0.49 |
| ▸ | CCR3 | P51677 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | ATF4 | P18848 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676228 | 1.00 | ABCB11 (0.75) | ABCB11CCR1HRH1CCR3LMNA | |
| SCHEMBL3676647 | 0.92 | ABCB11 (0.63) | ABCB11CCR1HRH1CCR3LMNA | |
| SCHEMBL3677923 | 0.92 | ABCB11 (0.63) | ABCB11CCR1HRH1CCR3LMNA | |
| SCHEMBL14607024 | 0.92 | ABCB11 (0.63) | ABCB11CCR1HRH1CCR3LMNA | |
| SCHEMBL3810709 | 0.90 | ABCB11 (0.83) | ABCB11CCR1HRH1CCR3LMNA | |
| SCHEMBL1683017 | 0.90 | ABCB11 (0.83) | ABCB11CCR1HRH1CCR3LMNA | |
| SCHEMBL14093760 | 0.89 | ABCB11 (0.79) | ABCB11CCR1HRH1CCR3LMNA | |
| SCHEMBL13508849 | 0.88 | ABCB11 (0.59) | ABCB11CCR1HRH1CCR3LMNA | |
| SCHEMBL3805993 | 0.87 | ABCB11 (0.79) | ABCB11CCR1HRH1CCR3LMNA | |
| SCHEMBL3809421 | 0.87 | ABCB11 (0.79) | ABCB11CCR1HRH1CCR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1922074-B1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA. | ASTRAZENECA AB (SE) | 2010-02-17 | — | — | EP | claimed |
| US-20090298875-A1 | A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | claimed |
| US-20090215732-A1 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | claimed |
| US-20080194632-A1 | Novel Piperidine Derivatives as Chemokine Receptor Modulators Useful for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | claimed |
| US-20090298875-A1 | A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090215732-A1 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20080194632-A1 | Novel Piperidine Derivatives as Chemokine Receptor Modulators Useful for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215732-A1 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | NR3C1, NR3C2, CHRM3 | ABCB11 1725/4885CCR1 71/4885HRH1 144/4885 |
| US-20080194632-A1 | Novel Piperidine Derivatives as Chemokine Receptor Modulators Useful for the Treatment of Respiratory Diseases | ACKR3, CCR5, CCR2 | ABCB11 760/4885CCR1 4/4885HRH1 129/4885 |
| US-20090298875-A1 | A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ADRB2, ADRB1, CHRM2 | ABCB11 2624/4885CCR1 242/4885HRH1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.